Therapeutic Vaccines

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Therapeutic vaccines have faced numerous setbacks in recent years. The only three vaccines to reach the market have had insignificant sales, while the pipeline has seen numerous high-profile failures and no new product launches in three years. However, new 'off-the-shelf' generalized vaccines driven by genomic advances promise to remedy the commercial drawbacks of early personalized vaccines


Scope

  • In-depth coverage of over 200 marketed and pipeline therapeutic vaccines, including forecasts for sales up to 2010 and analysis of future trends
  • Profiles of 16 leading therapeutic vaccines companies, their strategic position, pipelines, partnerships and financial outlook
  • Discussion of the many challenges facing therapeutic vaccine developers, and how technology evolution is driving the industry forward
  • Analysis of big pharma's level of interest in the sector, their partnerships and pipelines


    • Report Highlights
    Polyvalent, patient-specific vaccines have major commercial disadvantages that have limited their uptake. However, rapid scientific progress means that antigen-specific, generalized vaccines could soon offer comparable efficacy, to complement their strong commercial profile. As a result generalized vaccines are starting to dominate the pipeline.

    Therapeutic vaccines development is seeing an increasing trend towards the use of multiple antigens (and adjuvants), to attack cancers or HIV from multiple angles. Combinations of therapies, and novel approaches such as prime-boost regimens are expected to yield exciting results. Partnerships will therefore become much more important

    Therapeutic vaccine development is currently heavily weighted towards cancer vaccines, which account for 60.6% of all pipeline projects. However, the early-stage pipeline is starting to show greater interest in other therapeutic areas, from HIV and infectious disease to nicotine addiction, CNS and cardiovascular diseases


    Reasons to Purchase

  • Understand the scientific and commercial issues that are impeding therapeutic vaccines, and learn how they can become a success in the future
  • Assess the entire pipeline of therapeutic vaccines with an interactive Excel model containing details of over 200 therapeutic vaccines in development
  • Analyze and benchmark leading companies' strategies and pipelines, as well as big pharma's interest in the sector

    • Table of Contents

    Other users found this report page using the following search terms: therapeutic vaccines immunotherapy vaccines therapeutic rate marketed shock growth setback success swot therapy

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.